RadPharm, an imaging CRO, appointed Steven Owens as chief information officer. “We are delighted to welcome someone of Steve’s caliber to RadPharm. This key appointment affirms our commitment to continue providing best-in-class services and technologies to current and future RadPharm clients”, said Ronald Berg, CEO. “Steve’s vast knowledge of medical imaging technology and leadership experience will be instrumental in driving our IT strategy as we grow our infrastructure.”

Pharm-Olam International, a full service contract research organization (CRO), will now supply electronic adverse event management and reporting. “Pharm-Olam provides sponsors timely evaluation and reporting for adverse events to ensure all regulatory timelines are met in compliance with ICH, FDA and EMEA standards,” said Iain Gordon, global VP of business development. “With our skills in many languages and knowledge of local medical practices, we can communicate clearly with reporters to make sure we receive complete information for each safety event. Our system also allows sponsors to monitor safety data early to identify product risks and trends.” Here’s the release.

Private Access and Genetic Alliance announced a new partnership to protect patient privacy and create a faster and cheaper way for researchers to find patients for research. Leaders of the organizations say that their effort will help transform today’s medical research environment. “Our vision for harmonizing privacy and access through a suite of web-based software applications is ideally suited to the needs of those who suffer from chronic illness and genetic diseases,” said Private Access’ founder and CEO, Robert Shelton. Private Access is building a system to give individuals more control over exactly when and how others can use their medical information.

Commonwealth Biotechnologies reported financial results for the second quarter. Revenues were $3.2 million, an increase of 14 percent. The company reported a second quarter loss of $800,000. The company is upbeat. “Significant resources have been invested in the establishment of Venturepharm Asia, Commonwealth’s China-based joint venture formed with its largest shareholder, Venturepharm Laboratories. This joint venture continues to be a key strategy for the company to expand its production capabilities and offer high quality scientific services at globally competitive prices to its clients,” said Richard Freer, chairman and COO. Here’s the release.

OmniComm Systems announced that the company is providing electronic data capture (EDC) for a Phase II trial run by Systems Medicine. Systems Medicine initially began its relationship with OmniComm through the firm’s CRO program. “Our initial experience in working with OmniComm was very favorable and as a result, we chose to use them in our next trial. We were impressed with their responsiveness and professionalism throughout the entire negotiation and study build process,” said Patrick Shannon, senior director of project management at Systems Medicine. Here’s the release.

Akaza Research said that OpenClinica, its open-source electronic data capture solution, was selected by Retina Implant AG, a German medical device manufacturer. “We are currently using OpenClinica for eleven trials with sites in Germany, India, and Brazil, and we plan to use it for new studies with sites in the U.S. as well,” said Retina Implant’s Anusch Hekmat, VP of quality management & regulatory affairs. “As a small medical device company, the professional open source approach behind OpenClinica makes a lot of sense. It allows us to be highly adaptable in how we administer our clinical trials while providing us with high quality professional support in key areas.” Here’s the release.

Have a news release? Send it to .